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Background. The performance of clinical and immunological criteria to predict virological failure in HIV-infected children receiving 
antiretroviral therapy (ART) is not well documented.
Objective. To determine the validity of clinical and immunological monitoring in detecting virological failure in children on ART.
Methods. A total of 218 children were included in the study. All were from care and treatment clinics in Dar es Salaam, Tanzania. Their 
mean age was 10.6 years, 122 (56.0%) were males, and the mean time on ART was 40.9 months. The study was conducted from August 
2011 to March 2012. Data on sociodemographic and clinical characteristics and immunological and virological failure were based on World 
Health Organization definitions. Blood samples were collected for CD4+ T-cell count and viral load tests.
Results. Of 217 children with available viral load results, 124 (57.1%) had virological failure (>400 copies/mL), 25.0% immunological failure 
and 11.5% clinical failure. The sensitivity, specificity, positive predictive value and negative predictive value of clinical criteria were 12.9%, 
90.3%, 64.0% and 43.8%, respectively, those for immunological criteria 22.6%, 73.1%, 53.3% and 41.4%, and those for the combination of 
clinical and immunological monitoring 25.8%, 69.9%, 53.3% and 41.4%. Children who received nevirapine (NVP)-based regimens were 
two times more likely (odds ratio 2.0; 95% confidence interval 1.20 - 3.64) to have virological failure than those on efavirenz and protease 
inhibitor-based regimens.
Conclusions. The study demonstrated poor performance of currently recommended clinical and immunological criteria for monitoring 
HIV-infected children on ART. Moreover, children on NVP-based regimens had a higher risk of developing virological failure than those 
on other regimens.
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Globally, it is estimated that 3.4 million children 
under the age of 15 years are living with HIV 
and AIDS, the majority residing in sub-Saharan 
Africa and southern and southeastern Asia.[1] In 
Tanzania, the exact number infected with HIV 
is unknown. However, 130 000 - 160 000 children are eligible 
for antiretroviral therapy (ART).[2] The use of ART in Tanzania 
increased from <1% of those meeting eligibility criteria in 2004 
to 26% in 2012.[3]
The World Health Organization (WHO) advocates a public health 
approach to ART, recognising the potential role of plasma HIV-1 RNA 
testing but recommending clinical and immuno logical monitoring in 
resource-constrained countries such as Tanzania.[4,5] It has been shown 
that there are challenges related to the use of clinical and immunological 
parameters to detect virological failure in adults receiving ART. The delay 
in recognition may result in increased acquisition of HIV drug-resistant 
mutations as well as increased morbidity and mortality.[6] However, there 
may be no clear benefit to routine measurement of viral load to ascertain 
virological failure in adults.[7] Data on clinical and immunological 
monitoring to detect virological failure in children are limited. Where 
methods for detecting virological failure are available, they are not 
affordable. The aim of the current study was therefore to determine 
the validity of clinical and immunological monitoring in detecting 
virological failure among Tanzanian HIV-infected children on ART.
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Methods
Study design and population
A cross-sectional, health facility-based study was conducted from 
August 2011 to March 2012. A total of 218 HIV-infected children 
on ART were included. All were from care and treatment clinics in 
Dar es Salaam, the sites involved being Muhimbili National Hospital, 
Temeke, Amana, Mwananyamala, Infection Disease Control (IDC) 
and Sinza. The mean age of the children was 10.6 years (range 1  - 
16), and 122 (56.0%) were males. The mean duration of time on 
ART was 40.9 months. The cohort group involved those who had 
been receiving ART for ≥6 months. Ethical approval was obtained 
from the Senate Research and Publications Committee of Muhimbili 
University of Health and Allied Sciences, Dar es Salaam. Written 
informed consent was obtained from the parents/guardians.
Sociodemographic and clinical characteristics including start 
date of ART, type of ART regimen, WHO HIV disease stage and 
incidence of opportunistic infections were recorded. Clinical failure 
was defined as new or recurrence of WHO HIV disease stage III 
or IV events after ≥6 months of ART.[2] Immunological failure was 
defined as a CD4+ count below baseline after at least 6 months of 
ART or a drop in the CD4+ count to <30% of the peak level. To 
confirm the clinical and/or immunological failures, virological 
failure was defined as a viral load >400 copies/mL in children 
receiving ART for ≥6 months.
CD4+ counts and HIV viral loads
Blood samples were collected for determination of CD4+ T-cell 
counts (FACSCalibur system, Becton Dickinson, USA) and viral 
load tests (Roche Cobas Amplicor HIV-1 RNA monitor version 1.5 
assay, Roche Diagnostics, USA). The assay detection limit using 
standard protocol testing was 400 - 750 000 copies/mL, and a viral 
load <400 copies/mL indicated good response to ART. Testing was 
performed at the Department of Microbiology and Immunology 
laboratory, Muhimbili University of Health and Allied Sciences, 
Dar es Salaam.
Statistical analysis
Data were analysed using the Statistical Package for Social Scientists 
(SPSS) version 17.0, and sensitivity, specificity and predictive values 
of clinical and immunological criteria were calculated. Viral load was 
used as a reference method. The χ2 test was used to assess association 
between virological failure and clinical and immunological failures, 
opportunistic infections, ART regimen and WHO HIV disease stage. 
A p-value of <0.05 was considered statistically significant. Logistic 
regression analysis was performed to determine the predictors 
associated with virological failure. Odds ratios (ORs) and 95% 
confidence intervals (CIs) are presented as the risk estimator.
Results
A total of 218 children on ART were included in the study. Of these, 
122 (56.0%) were males. The largest age group was 11 - 15-year-
olds (80 children, 36.7%). The mean age for the group as a whole 
was 10.6 years (range 1 - 16), and the mean duration of time on 
ART was 40.9 months. One hundred and fifty-three (70.2%) and 
53 (23.4%) children were in WHO HIV disease stages III and IV, 
respectively (Table 1). One hundred and forty-seven (67.4%) were on 
nevirapine (NVP)-based regimens. Eighty-five (39.0%) had a history 
of opportunistic infections while on ART. Pulmonary tuberculosis 
was the most common opportunistic infection reported.
The median viral load was log 3.0. Twenty-five (11.5%) and 54 
(25.0%) children had clinical and immunological failures, respectively, 
and 60 (27.5%) had both clinical and immunological failures. The 
sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value of clinical, immunological and combined monitoring 
are summarised in Table 2. Immunological monitoring had a higher 
sensitivity (22.6% v. 12.9%) but lower specificity (73.1% v. 90.3%) 
than clinical criteria. Combined clinical and immunological criteria 
Table 1. Baseline sociodemographic, clinical and immuno-
logical characteristics of the study population (N=218)
Characteristics n (%)
Age (years)
1 - 5 34 (15.6)
6 - 10 66 (29.8)











NVP, NRTI 147 (67.4)
EFV, NRTI 59 (27.1)
PI, NRTI 11 (5.0)
NRTI 1 (0.5)
Duration of time on ART (months)
6 - 30 95 (43.6)
31 - 55 63 (28.9)
56 - 79 38 (17.4)
≥80 22 (10.1)
Opportunistic infection 85 (39.0)
Pulmonary tuberculosis 35 (16.1)
Recurrent pneumonia 23 (10.6)
Skin and mucosal lesion 8 (3.7)
Chronic ear discharge 7 (3.2)
CNS HIV-related manifestations 7 (3.2)
HIV-related malignancy 5 (2.3)
CD4+%
0 - 15 9 (4.1)
16 - 25 20 (9.2)
≥26 5 (2.3)
CD4+ count (/µl)
0 - 200 59 (27.1)
201 - 350 31 (14.2)
351 - 500 42 (19.3)
≥501 52 (23.1)
WHO = World Health Organization; ART = antiretroviral therapy; NVP = nevirapine;  
NRTI = nucleoside reverse transcriptase inhibitors; EFV = efavirenz; PI = protease inhibitor; 
CNS = central nervous system.
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had higher sensitivity but lower specificity in detecting virological 
failure (Table 2).
To assess the association of certain immunological and clinical 
variables with virological failure in this cohort, we performed 
univariate and multivariate analysis. The use of NVP was a predictor 
for virological failure (Table 3), showing a two times higher risk than 
other regimens (OR 2.0; 95% CI 1.20 - 3.64; p=0.03).
Discussion 
Proper monitoring of children on ART is key to preventing emergence 
of HIV drug resistance, but it can be challenging in resource-limited 
settings. In this study, we showed that the proportion of children on 
ART with virological failure was highest, followed by immunological 
and clinical failure. Clinical and immunological criteria showed 
poor sensitivity and specificity for detection of virological failure 
in children on ART, and all the children had a detectable viral load 
despite being on ART for ≥6 months (the defined period for viral 
suppression to an undetectable level). NVP-based regimens were 
independent significant predictors of virological failure in children 
on ART.
The rate of virological failure in this study was high (57%) 
compared with those reported in previous studies: 20% in Thailand,[8] 
26% in Uganda,[9] 32% in the Kilimanjaro region, Tanzania,[10] and 
50% in Cote d’Ivoire.[11] The differences observed between the current 
and previous studies could be explained by the different viral load 
cut-off points used, e.g. >1 000 copies/mL to indicate virological 
failure was used in the Thailand study. The Uganda study was a 
prospective cohort study as opposed to our cross-sectional study, 
which could have resulted in closer medical attention and monitoring 
of participants. However, the participants in the two studies were of 
similar ages.
Some of reasons for the low sensitivity of immunological criteria 
for virological failure in HIV-infected children on ART have been 
found to be opportunistic infections, individual variation, and 
evidence that HIV-specific CD4+ T cells increase when the viral load 
increases.[12] Immunological criteria were two times more sensitive 
than clinical criteria in the current and previous studies, supporting 
the concept that immunological failure occurs earlier than clinical 
failure.[13] When a combination of clinical and immunological criteria 
was used, the sensitivity and specificity to predict virological failure 
were 25.8% and 69.9%, respectively. The combination of clinical and 
immunological criteria therefore had higher sensitivity but relatively 
low specificity in predicting virological failure, i.e. the combination of 
the two criteria offers a better chance of predicting virological failure 
than a single criterion, but at the expense of lower specificity.
Our findings are in agreement with those of previous studies 
conducted elsewhere. In a prospective cohort study of children 
aged <16 years in South Africa by Davies et al.,[14] the sensitivity 
of immunological criteria was 10.0%, with a PPV of 42.0%, and 
immunological criteria were therefore unable to identify children 
on ART who were failing virologically. A study to determine the 
performance of combined clinical and immunological criteria by 
Lynen et al.[15] showed that combining clinical and immunological 
criteria resulted in sensitivity of 29 - 33%, which is comparable 
to the current study findings. A recent study from Thailand by 
Bunupuradah et al.[16] examining the accuracy of immunological 
failure in predicting virological failure in HIV-infected children on 
first-line ART showed that immunological failure had a sensitivity 
of 20.4% and specificity of 93.9% in predicting the virological failure, 
comparable to our study.
Our study and previous studies from Uganda and Thailand,[8,9] 
showed that children on NVP-based regimens were more likely 
to have virological failure than those on efavirenz and protease 
inhibitor-based regimens. In the current study, more than two-thirds 
of the children received NVP-based regimens. There is evidence that 
use of single-dose NVP prophylaxis during labour leads to selection 
of NVP-resistant strains.[17] Pre-exposure of children to NVP via their 
mothers as part of prevention of mother-to-child transmission of HIV 
may have predisposed to drug resistance and therefore virological 
failure; however, we did not examine this effect. Furthermore, in the 
current study most children received an NVP-based regimen. Since it 
was a cross-sectional study, it was not possible to establish the trend of 
Table 2. Performance characteristics of clinical, immunological and combined criteria in predicting virological failure in HIV-
infected children on ART (N=217 )
Criteria Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Clinical (n=25) 12.9 90.3 64.0 43.8
Immunological (n=54) 22.6 73.1 52.8 41.5
Combined clinical and immunological (n=60) 25.8 69.6 53.3 41.4
ART = antiretroviral therapy; PPV = positive predictive value; NPV = negative predictive value.
Table 3. Predictors of virological failure among children on ART for ≥6 months
Univariate analysis Multivariate analysis
Predictor OR (95% CI) p-value OR (95% CI) p-value
Age (<59 mo. v. ≥60 mo.) 1.05 (0.46 - 2.44) 0.90 0.73 (0.38 - 1.37) 0.30
Duration on ART (6 mo. v. ≥7 mo.) 1.40 (0.50 - 3.97) 0.5 1.40 (0.40 - 4.02) 0.50
ART regimen (NVP-based v. other regimens) 1.80 (0.99 - 3.10) 0.05 2.0 (1.20 - 3.64) 0.03
WHO HIV disease stage (IV v. I - III) 1.03 (0.40 - 2.46) 0.9 1.03 (0.40 - 2.52) 0.90
OIs v. no history of OIs 1.05 (0.60 - 1.80) 0.87 0.93 (0.50 - 1.60) 0.75
CD4+ count <350 cells/µl or CD4+% >25% 0.67 (0.12 - 4.06) 0.67 1.78 (0.21 - 15.50) 0.60
OR = odds ratio; CI = confidence interval; ART = antiretroviral therapy; NVP = nevirapine; WHO = World Health Organization; OIs = opportunistic infections.
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viral suppression and viral rebound occurring over a period of time. 
In addition, since viral load assessment is not a routine investigation 
in resource-limited settings such as ours, baseline viral load samples 
were not available for testing in this study.
In conclusion, we showed that the proportion of virological failure 
was the highest (57.1%), followed by immunological (25.0%) and 
clinical failure (11.5%). Children who were on NVP-based regimens 
had a higher risk of developing virological failure than those on other 
regimens. The study demonstrated poor performance of currently 
recommended clinical and immunological criteria to monitor HIV-
infected children on ART. Expanding access to viral load testing may 
improve outcomes for children on ART in Tanzania and help doctors 
make informed decisions on treating HIV-infected children.
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